HNN3.0

Project cooperationUpdated on 21 January 2026

Clinical collaboration for thyroid cancer and thyroid disease biospecimen collection

Associate Professor of Surgery, University of Cagliari at University of Cagliari (UNICA)

Cagliari, Italy

About

Our clinical unit is available to collaborate within a Horizon project by providing access to surgical thyroid specimens and associated biological materials from patients undergoing surgery for thyroid cancer and other thyroid pathologies. We routinely perform around 400 thyroidectomies annually, ensuring a stable recruitment base and consistent availability of samples across a broad spectrum of thyroid conditions.

Within a project framework, we can:

  • Collect surgical thyroid tissue specimens generated during standard-of-care procedures (e.g., tumor and non-tumor tissue, when applicable).

  • Collect and provide additional biological samples as defined by the protocol (e.g., blood-derived samples or other biospecimens, depending on study needs and feasibility).

  • Process, store, and prepare samples for transfer, and ship biospecimens to project partners, in accordance with agreed SOPs and applicable ethical/legal requirements.

  • Support clinical annotation of samples (e.g., basic demographics, diagnosis, surgical details, pathology results, outcomes), subject to approvals and data governance.

This cooperation is intended for partners seeking clinically sourced biospecimens to enable translational research, biomarker discovery/validation, molecular profiling, or the development of diagnostic/prognostic tools in thyroid oncology and thyroid disease. Sample types, handling requirements, timelines, and data fields can be aligned to the consortium protocol.

Topic

  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

  • Partner seeks Consortium/Coordinator

Organisation

University of Cagliari (UNICA)

University

Cagliari, Italy

Similar opportunities

  • Project cooperation

    NAM: organoids and OoC for drug discovery, and precision medicine applications

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Una Riekstina

    full professor at Department of Pharmaceutical Sciences, University of Latvia

    Riga, Latvia

  • Project cooperation

    Study the impact of climate change in the development and progression of Parkinson´s disease

    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Laura Gómez Cuadrado

    Head of Biomedicine and Cellular Toxicology at University of Burgos

    Burgos, Spain

  • Project cooperation

    Clinical Laboratory for Respiratory Pathogen Diagnostics and Validation

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Vel Murugan

    Professor at AZ Board of Regents on behalf of Arizona State University

    Tempe, United States